Compare EIC & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIC | SABS |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.3M | 201.4M |
| IPO Year | N/A | N/A |
| Metric | EIC | SABS |
|---|---|---|
| Price | $9.41 | $3.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $12.63 | $9.80 |
| AVG Volume (30 Days) | 149.3K | ★ 822.8K |
| Earning Date | 02-26-2026 | 05-08-2026 |
| Dividend Yield | ★ 13.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.17 | $1.09 |
| 52 Week High | $14.83 | $6.60 |
| Indicator | EIC | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 43.96 |
| Support Level | $9.25 | $3.69 |
| Resistance Level | $10.15 | $4.16 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 52.27 | 20.97 |
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.